ArticleInternational journal of oncology2022

Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer.

Sofia Isolde Bär et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.